| 1 |
Marini F, Giusti F, Tonelli F, Brandi ML. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. Int J Mol Sci 2021;22:4041. [PMID: 33919851 DOI: 10.3390/ijms22084041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Marini F, Giusti F, Tonelli F, Brandi ML. Multiple endocrine neoplasia type 1: a review of current diagnostic and treatment approaches. Expert Opinion on Orphan Drugs 2020;8:367-77. [DOI: 10.1080/21678707.2020.1811086] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Dai C, Liang S, Sun B, Li Y, Kang J. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Front Oncol 2021;11:773905. [PMID: 34869016 DOI: 10.3389/fonc.2021.773905] [Reference Citation Analysis]
|
| 4 |
Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Reference Citation Analysis]
|
| 5 |
Lewis MA. Hereditary Syndromes in Neuroendocrine Tumors. Curr Treat Options Oncol 2020;21:50. [PMID: 32350690 DOI: 10.1007/s11864-020-00749-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Gläsker S, Vergauwen E, Koch CA, Kutikov A, Vortmeyer AO. Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets Ther 2020;13:5669-90. [PMID: 32606780 DOI: 10.2147/OTT.S190753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 7 |
Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021;42:133-70. [PMID: 33249439 DOI: 10.1210/endrev/bnaa031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
